NewsBenzinga先前报道:Revolution Medicines 的 RASONQUE 联合化疗在 61 名一线转移性胰腺癌患者中,于 18.3 个月中位随访时显示 60.7% 的确认客观缓解率(ORR)和 8.2% 的完全缓解;支持 III 期 RASolute 303 研究 先前报道:Revolution Medicines 的 RASONQUE 联合化疗在 61 名一线转移性胰腺癌患者中,于 18.3 个月中位随访时显示 60.7% 的确认客观缓解率(ORR)和 8.2% 的完全缓解;支持 III 期 RASolute 303 研究 Benzinga 2026.11.20 05:38 (GMT+0) Open on Benzinga Other news Geospace Technologies (GEOS) Shares Tumble 16.47% After Hours: Here's Why Stock Market: Will S&P 500 Open Up or Down Today? Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY Morning Bid: Anthropic's splashy IPO fails to lift AI boat Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303 Onfolio Holdings (ONFO) Stock Drops 16.80% After Hours: Here's What Investors Should Know
Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303